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Introduction
With the development of next generation sequencing (NGS) 
technology, there has been a dramatic increase in our 
knowledge and accelerated understanding of the molecular 
pathology of various cancer types, including pancreatic 
cancer (PC). PC remains the most lethal solid tumour type 
in humans, with little improvement in outcome over the 
last few decades. There are few effective therapies available 
for patients with advanced disease and as a result PC is 
predicted to become the 2nd leading cause of cancer death 
in the West by 2025 (1). A major challenge of translating 
recent genomic and pre-clinical discoveries in PC into 
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clinical practice for precision medicine has been the 
implementation of real time molecular profiling of patients 
to inform clinical decision making. NGS has revolutionised 
our ability to classify patients into potential responsive 
subgroups through molecular profiling, however, the 
majority of these studies were performed using early stage, 
non-metastatic resected specimens (2-7). Even though NGS 
from core biopsies of metastatic lesions can be done with 
high success rates in PC (8,9), a large proportion of patients 
present with metastatic lesions that are not amenable to 
percutaneous biopsy due to anatomical location or size. 
This presents a significant challenge to obtain tissue for 
molecular phenotyping in all patients with PC, particularly 
in patients with localised disease. Thus, there is an urgent 
need to develop strategies to safely acquire sufficient quality 
tissue suitable for NGS for the entire spectrum of PC 
(resectable, locally advanced, metastatic) to enable precision 
medicine opportunities in real world clinical practice.
There has been significant progress in the use of 
endoscopic ultrasound (EUS) in the diagnosis and 
management of PC in the last decade (10-13). The 
development of next generation fine needle core biopsy 
needles has increased the quality and quantity of tissue 
samples that are obtained even from low epithelial content 
tumours which is a histopathological characteristic of PC 
(14,15). This provides an alternative to percutaneous biopsy 
for patients presenting with de novo PC irrespective of 
clinical stage. 
Many studies describing the use of tumour biopsies, 
including EUS guided, for therapeutic stratification in PC 
have failed to describe the patient denominator included 
in the studies from the outset (8,13,15). In addition, 
utilising diagnostic samples for molecular analysis, has 
been associated with high failure rates in many cancer types 
including PC in previous studies (16-19). Therefore, the 
real world feasibility and clinical utility of EUS guided 
biopsies to enable NGS is not thoroughly investigated.
To address these challenges with the aim of facilitating 
real world personalised clinical trials in all clinical stages 
of PC, we developed a clinical patient pathway embedding 
translational research that allows NGS molecular 
phenotyping using diagnostic EUS guided biopsies in 
parallel and complementary to the standard diagnostic 
process. 
Methods
Patients presenting with a pancreatic mass suspicious 
of PC between 2016–2018 were referred to a fast-
track, early assessment EUS clinic in a single institution 
(Glasgow Royal Infirmary). Ethical approval was obtained 
for collecting additional research biopsies from patients 
undergoing EUS guided biopsies for investigation of 
possible PC (Ethical approval number: 17/WS/0085). 
Patient consent included extra biopsies of pancreatic 
lesions if deemed appropriate by performing clinician. 
Matching venous blood was taken for normal genome 
analysis and freshly frozen. Upon EUS evaluation, lesions 
suspicious of PC, IPMN or pancreatic neuroendocrine 
tumour (PNET) was sampled for diagnosis and genome 
sequencing.  This  increased the  number  of  EUS 
needle passes from 2 or 3 to 4 or 5 per patient. Where 
appropriate, liver metastases (n=2) and lymph node 
metastases (n=1) were taken for comparative sequencing. 
Samples were either fresh frozen or stored in formalin 
prior to DNA/RNA extraction (Figure S1). Formalin 
fixed paraffin embedded (FFPE) diagnostic samples were 
fixed in a commercial methanol fixative in the endoscopy 
room (PreservCyt®). Fresh frozen samples underwent 
cryosection, whilst FFPE samples underwent standard 
tissue section and stained with haematoxylin and eosin 
(H&E). Histopathological assessment of diagnostic and 
fresh frozen H&E slides was performed by a Specialist 
Pancreatic Pathologist. If the diagnostic specimen was 
inconclusive, the fresh frozen research sample was utilised 
for diagnostic purposes. Samples identified for sequencing 
underwent histological cellularity assessment and areas 
containing tumour epithelium was identified and marked 
on the H&E slide. In the case of fresh frozen samples, all 
samples underwent macro-dissection to enrich for tumour 
epithelium prior to DNA and RNA extraction. Library 
preparation, DNA/RNA extraction and nucleic acid 
sequencing are fully described in the Supplementary File.
Results 
Clinical implications of utilising EUS biopsies for NGS
During the study period, 90 patients were used as a 
training set to develop the molecular profiling pathway to 
enable clinical feasibility (Table 1, Figure S2). The majority 
of patients (n=82, 91%) had a pathological diagnosis 
obtained from the initial EUS biopsy. The others were 
confirmed on repeat EUS (n=6) or laparoscopy (n=2) 
and 1 patient failed to obtain a histological diagnosis 
despite multiple attempts. The majority of patients were 
Chinese Clinical Oncology, Vol 8, No 2 April 2019
© Chinese Clinical Oncology. All rights reserved.   Chin Clin Oncol 2019;8(2):16cco.amegroups.com
Page 3 of 9
diagnosed with PC (n=65) and only 2 patients (2%) 
suffered morbidity during the admission of their diagnostic 
EUS. Both developed acute pancreatitis and subsequent 
temporary acute kidney injury after endoscopic retrograde 
cholangiopancreatography (ERCP). 
EUS guided biopsies provide sufficient DNA and RNA 
yields for NGS
A major challenge to utilising EUS biopsies for molecular 
profiling is the perceived low DNA yields obtained from 
traditional fine needle aspirates. The DNA yield obtained 
from both fresh frozen and FFPE samples were sufficient 
using a variety of needles for targeted NGS, as well as 
whole genome sequencing (WGS) in the majority (73%) 
of patients with fresh frozen biopsy (Table 1). Fresh frozen 
biopsies allow sufficient RNA for whole transcriptome RNA 
sequencing in the majority of specimens (Table 1). Only 
1 of the n=86 fresh frozen EUS guided biopsies provided 
insufficient DNA for sequencing, making the overall nucleic 
acid yield success rate of >98%.
To broaden the clinical utility and translational potential 
of this approach, a protocol was developed to test the 
diagnostic, FFPE samples to be utilised for NGS. A 
training set of 14 diagnostic FFPE samples were used for 
DNA extraction and all produced sufficient DNA (>100 ng) 
for targeted capture sequencing. Of these, 9 had matched 
fresh frozen biopsies that were processed and sequenced 
in parallel. In addition, FFPE diagnostic biopsy samples 
from 45 prospective patients enrolled in the PRECISION-
Panc clinical trial platform demonstrated only 1 DNA 
extraction failure (Table 2). Of these, 27 were EUS biopsies 
and 19 percutaneous core biopsies of various metastatic 
lesions (Table 2). The only extraction failure was from a liver 
metastasis percutaneous biopsy due to insufficient material.
EUS guided biopsies can be utilised for targeted panel 
sequencing
A cohort of consecutive patients (n=41) undergoing 
EUS biopsy underwent targeted capture, transcriptome 
(RNAseq) and whole genome (WGS) sequencing. The 
majority of patients had a diagnosis of PC (n=36, 87.8%) 
followed by pancreatic neuroendocrine tumour (n=3, 7.3%), 
Cholangiocarcinoma (n=1, 2.4%) and 1 patient with a 
pancreatic metastasis from a primary lung cancer (Table 3). 
Of the 36 patients with PC, 13 had borderline resectable/
resectable disease (36.1%), 11 had locally advanced (30.6%) 
and 12 presented with metastatic (33.3%) disease (Table 3). 
Targeted capture sequencing was performed following 
extraction of DNA (>50 ng). KRAS mutations were detected 
in 39 out of 42 samples (93%) from 25 out of 26 patients 
Table 1 DNA and RNA yield from EUS core biopsy needles
EUS needle type Size (G)
Fresh frozen
DNA yield [mean, range (ng)] RNA yield [mean, range (ng)]
Boston Acquire® 22 1,819 (133–7,350) 191 (30–1,187)
Sharkcore® 19 2,170 (11.4–6,000) N/A
Sharkcore® 22 2,939 (1,134–7,595) 481 (40–1,790)
Cook Procore® 20 1745 (290–4,750) 18 (3.6–44)
EUS, endoscopic ultrasound; N/A, not available.
Table 2 DNA and RNA yield from EUS guided FFPE biopsies
Patient cohort Needle size (G)
FFPE
DNA yield [mean, range (ng)] RNA yield [mean, range (ng)]
Training set (n=14) 22 1,819 (133–7,350) 191 (30–1,187)
PRECISION-Panc EUS set (n=27) 22 2,694 (102–28,600) N/A
PRECISION-Panc Core set (n=19) Various 550 (0–1,730)
EUS, endoscopic ultrasound; FFPE, formalin fixed paraffin embedded; N/A, not available.
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(96%). Only 1 sample was deemed a sequencing failure 
(EUS 16) based on quality control metrics but demonstrated 
a mutational profile consistent with PC (Figure 1). In 1 
patient with no detectable KRAS mutation (EUS 22), there 
was a BRAF mutation suggesting that this was a true KRAS 
wild-type PC and not due to a sequencing failure (Figure 1). 
The mean allelic frequency of mutated KRAS appeared 
to correlate with histological tissue cellularity estimates, 
with very low KRAS frequency (<10%) being associated 
with histological cellularity <10% (Figure 1). Well known 
mutations in TP53 (78%), CDKN2A (34%) and SMAD4 
(32%) were identified in keeping with previous studies 
(Figure 1) (2-4). Potentially actionable mutations were 
identified in a sub-group of patients, including ATM (12%) 
and BRCA1 (6%) (Figure 1). FFPE biopsies performed 
satisfactorily and provided sufficient DNA that is suitable 
for targeted capture sequencing (Table 2). Based on quality 
control analysis, these were above the thresholds required 
to call observed mutations (Table S1). Furthermore, the 
mutational profile obtained from FFPE samples were 
almost identical to the matched paired fresh frozen sample 
in both point mutation and copy number analyses (Figure 2). 
EUS guided biopsies can be utilised for WGS 
Due to the often-rapid emergence of resistance there is 
an urgent need to assess tumour evolution in response to 
therapeutics (20). In order to investigate these mechanisms 
including genomic rearrangements in addition to somatic 
mutations, WGS provides the most data. The feasibility of 
performing WGS using pre-treatment EUS biopsies was 
investigated with a proof of concept study of 5 selected 
samples based on molecular cellularity on panel sequencing 
(>25%), and available DNA quantity. In total, 31 of 
43 patients (72%) had samples with sufficient quantity DNA 
for WGS, and 5 were selected as a proof of principle study 
with no sequencing failures. Mutational signature analysis 
revealed signatures previously described in PC including 
the COSMIC BRCA mutational signature (Figure 3). Circos 
plots allow visualisation of genomic re-arrangements and 
demonstrate the high number of structural variation events, 
as seen in EUS4 (Figure 3). These data suggest that fresh 
frozen EUS samples can be used for WGS to enable novel 
investigative techniques into the clonal evolution of PC. 
RNA sequencing allows transcriptomic sub-typing of PC 
Molecular subtyping of tumours is becoming clinically 
relevant as therapeutic targets within subtypes are being 
identified and clinically tested (6). In order to allow 
treatment stratification based on molecular subtyping, 
the utility of RNAseq using EUS guided biopsies was 
investigated. Gene expression was normalised, and 
consensus clustering was performed on 35 PC based on 
gene programs described by Bailey et al. (2). We classified 
PC into the 2 main classes, squamous (n=19, 54%) and 
classical pancreatic (n=16, 46%) (6) (Figure 4). In the 2 
patients with matching primary and liver metastases the 
primary and metastatic lesions cluster to the same subtype, 
despite some differences in gene programs (Figure 4). 
Albeit only in small numbers, this demonstrates that 
transcriptomic profiling of both primary and metastatic 
lesion is feasible using this approach and should be tested in 
further studies. 
Discussion
Here we demonstrate that EUS guided biopsies can 
be utilised with high success rates in a routine clinical 
patient pathway for NGS analysis with the potential to 
enhance precision medicine and translational studies in 
PC. Importantly, acquiring extra biopsies at the same 
diagnostic EUS setting is associated with a high diagnostic 
rate without a significant increase in morbidity. At the 
same time, this eliminates the requirement for in-room 
cytopathology support at EUS. These results suggest that 
Table 3 Histological and clinical features of the EUS training  
cohort that underwent NGS
Variables n=41, (%)
Histological subtype
PC 36 (87.8)
PNET 3 (7.3)
Cholangiocarcinoma 1 (2.4)
Pancreas metastasis 1 (2.4)
Stage (PC only)
Resectable/borderline 13 (36.1)
Resectable
Locally advanced 11 (30.6)
Metastatic 12 (33.3)
EUS, endoscopic ultrasound; NGS, next generation sequencing; 
PC, pancreatic cancer; FFPE, formalin fixed paraffin embedded.
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Figure 1 Point mutations and copy number variations in the EUS biopsy cohort. Oncoplot demonstrating somatic mutations (coloured 
boxes) and copy number changes (arrows) are indicated for the EUS biopsy training cohort. Pathology, histological cellularity and KRAS 
mutant allele frequency are on the top X-axis. The majority of PC specimens identified well known mutations including KRAS, TP53, 
SMAD4 and CDKN2A. EUS, endoscopic ultrasound.
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Figure 2 Copy number alterations in fresh frozen and FFPE samples from the same primary tumour (EUS22). Example of copy number plot 
comparison between fresh frozen and FFPE biopsies. Significant copy number variations were equal in both samples. Well documented PC 
copy number loss in SMAD4 and CDKN2A are shown in both samples. The similarities seen between fresh frozen and FFPE samples were 
consistent in the FFPE versus frozen comparison set (n=9) and further demonstrates the utility of FFPE diagnostic EUS biopsies for targeted 
genomic profiling. FFPE, formalin fixed paraffin embedded.
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integrating research activities into routine clinical pathways 
is not detrimental to the quality of patient care and may 
further enhance it.
Panel sequencing from diagnostic EUS FNAs was 
previously shown to be feasible and able to identify potential 
actionable mutations (13). However, failure rates in using 
diagnostic samples was reported to be high and may result 
in a large proportion of patients requiring repeat research 
dedicated biopsies and subsequently being ineligible for 
personalised clinical trials. Our results demonstrate if 
sample acquisition is performed using a protocol tailored 
towards both diagnosis and NGS purposes, targeted capture 
sequencing can be performed with excellent success rates. 
Both fresh frozen and FFPE tissue provide sufficient DNA 
yields in almost all patients with high sequencing success 
rates (>90%). Using a number of paired fresh frozen and 
FFPE samples, our results demonstrate high concordance 
between both tissue acquisition and processing strategies. 
As a result, for ease of use and greater applicability across 
clinical units performing EUS, FFPE embedded biopsy 
tissue will be utilised for the PRECISION-Panc consortium 
(a clinical therapeutic development platform for pancreatic 
cancer, http://www.precisionpanc.org). 
The ability to perform a range of NGS profiling and 
analysis in different preservative conditions will greatly 
improve the armamentarium available to study and treat PC. 
Developing a PC specific targeted capture based molecular 
assay that identifies signatures of therapeutic vulnerabilities 
such as DNA damage repair (DDR) and mismatch deficiency 
is a priority. WGS is significantly more expensive and 
requires much larger storage capacity, and as of yet has not 
demonstrated superiority for therapeutic selection. On the 
other hand, in well-designed studies focussed on clonal 
evolution of PC, WGS of EUS biopsies and subsequent 
resection specimen has potential to facilitate unique insights 
into the development of therapeutic resistance following 
neoadjuvant treatment strategies (Table S1). Furthermore, 
RNAseq of EUS guided biopsies can provide opportunities 
for investigating molecular subtypes in advanced disease and 
potentially direct therapy in future clinical trials. 
The philosophy of PRECISION-Panc aims to provide 
clinical trial options for all patients with PC. The protocol 
developed here has been used successfully in >100 patients 
within the PRECISION-Panc master protocol. Ongoing 
evolution of this protocol and strategy is crucial as 
biomarkers of therapeutic response and molecular assays 
develop, to enable optimal patient selection for precision 
oncology in PC.
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Figure 3 Whole genome sequencing of EUS guided biopsies is feasible for translational research in PC. (A) Mutational signature 
contribution in 5 EUS samples that underwent WGS; color intensity of blue circles reflects relative contribution of each mutational signature; 
(B) circos plots demonstrating structural variations and copy number changes in EUS samples. EUS 4 reveals a high number of structural 
variations suggesting a high level of genomic instability. WGS allows in-depth study of tumour evolution and heterogeneity, whilst having the 
potential to reveal novel resistance mechanisms in the neoadjuvant and advanced disease settings. EUS, endoscopic ultrasound; WGS, whole 
genome sequencing; PC, pancreatic cancer.
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Figure 4 Transcriptomic profiling of PC using EUS guided biopsies. RNA sequencing of 35 patients across all clinical stages of presentation 
of PC is feasible and clinically relevant. (A) Molecular subtype can be identified using EUS guided biopsies (B) comparison between metastatic 
and primary PC demonstrate differences in gene programs 7–10 with loss of gene expression associated with the microenvironment (immune) 
and normal pancreatic signalling. PC, pancreatic cancer; EUS, endoscopic ultrasound.
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Endoscopic ultrasound biopsies: collection and 
extraction 
Patients were sedated and received analgesia as standard 
(Midazolam, Fentanyl and local anaesthetic throat spray) 
for EUS and underwent initial endoscopy and ultrasound 
assessment of the pancreaticobiliary tract. Patients with 
evidence of a mass suspicious of a pancreaticobiliary 
neoplasm was biopsied as standard. This was followed by 
1–3 additional samples for research purposes. Biopsies 
were taken using a fanning technique with a variety of EUS 
needles (discussed in Chapter 7). Diagnostic specimens were 
processed as standard using local collection protocols. This 
involved expelling all biopsies from the same lesion in a 
single pot of methanol based buffered preservative solution 
(ThinPrep Preservcyte, Hologic, inc. Cat No.: 85093-
001). Additional research biopsies that were preserved in 
methanol fixative and embedded in FFPE was processed 
in a similar fashion. An additional venous blood sample 
(4–5 mLs) were collected in standard EDTA blood tubes 
(e.g., BD Vacutainer® K2EDTA tube, Cat no. KFK171) as a 
source of germline DNA.
EUS biopsies underwent cryopreservation to enable 
next generation sequencing including RNA and whole 
genome sequencing. This is a novel protocol designed by 
the PhD candidate and not previously described. Additional 
biopsies [1–3] were expelled in 5–10 mL of PBS in a 
50 mL collection tube. This was gently swirled to allow 
excess blood to separate from the biopsy material. This was 
passed via a 70 μm nylon mesh cell strainer (Fisherbrand®, 
Cat No. 22363548) and the biopsy tissue transferred onto 
a metal histology mounting slide. This allowed the biopsies 
to all lie in a flat level plane, which enable cryosection at 
a later stage. The metal slide was transferred onto dry ice 
and the biopsies mounted in optimal cutting temperature 
(OCT) compound (VWR chemicals™, Cat No. 361603E) 
immediately. After the OCT has set, the mounted block and 
biopsies were removed from the mounting slide, placed in 
pre-labelled plastic cassette and transported to secure cold 
storage at −70 ℃.
Fresh frozen EUS biopsies underwent histological 
analysis prior to DNA extraction, provided the diagnostic 
specimen was conclusive. In cases where uncertainty 
remained regarding the diagnosis, the fresh frozen 
specimens were reprocessed and embedded in FFPE to be 
used as diagnostic samples. Cryosections were performed 
by the Beatson Institute of Cancer research histopathology 
unit. Sections were stained with haematoxylin and eosin 
(H&E) followed by formal assessment by a Consultant 
Pathologist with an interest in pancreatic cancer. Regions 
with tumour epithelium were marked on H&E slides and 
histological cellularity determined. Macro dissection was 
performed to enrich for tumour epithelium in the frozen 
specimens. This involved overlaying the marked H&E slide 
with the OCT frozen block, whilst keeping the frozen tissue 
on dry ice. The corresponding marked areas were dissected 
using a fresh scalpel blade for DNA and RNA extraction.
DNA and RNA extractions were performed using 
the AllPrep® DNA/RNA micro Kit from Qiagen© (Cat. 
No. 80284). Briefly, on ice, 600 μL of RLT Plus solution 
(AllPrep® Micro Kit) was added to macro dissected tissue 
and disrupted using a rotor-stator homogenizer (Polytron® 
PT1200E, KINEMETICA) in a glass test tube. The 
lysate underwent freezing and thawing to allow complete 
lysis followed by centrifuging to separate the supernatant 
from tissue fragments. The supernatant was added to an 
AllPrep® DNA spin column, centrifuged and stored at 4 ℃ 
for extraction. Six hundred μL of Ethanol was added to the 
flow-through (containing RNA and protein) and added to 
an RNA spin column and centrifuged. This was followed by 
buffer washing of the spin column multiple times. RNA was 
isolated by eluting the RNA from the column using RNase-
free water directly to the spin column (30–50 μL) and 
centrifuging for 1 minute at 8,000× g. DNA was isolated by 
buffer washing the DNA column and eluting the column 
with warmed elution buffer EB (AllPrep® Micro Kit). 
DNA and RNA were quantified using the Nanodrop® 2000 
spectrophotometer. DNA and RNA were stored at −80 ℃ 
until sequencing.
Patients enrolled in the PRECISION-Panc master 
protocol that underwent molecular profiling from EUS 
biopsies had samples preserved in methanol fixative and 
embedded in FFPE. The commercial fixative used may vary 
from site to site, provided it is a methanol fixative (similar 
to ThinPrep PreservCyte, Hologic, inc. Cat No.: 85093-
001). The PRECISION-Panc protocol requests patients to 
have a minimum of 3, but ideally 5, EUS biopsies collected 
and fixed in the same pot. Samples are then transferred 
to local pathology laboratory, where it is processed and 
embedded in formalin fixed paraffin embedded (FFPE) 
block for histological diagnosis followed by DNA and RNA 
extraction.
EUS biopsies are processed into FFPE blocks by 
retrieving all ‘micro-biopsies’ from the preservative pot 
using dedicated filter paper (CellPath™ tissuewrap). To 
avoid contamination, human fibrin or serum are not be used 
Supplementary
to make cell clots. These are next fixed for 12 to 24 hours in 
formalin and embedded as a paraffin block using standard 
histological techniques. Diagnostic H&E slide is taken, 
followed by cellularity estimation by dedicated Consultant 
Pathologist. An assessment on suitability for extraction and 
sequencing (sufficient tissue volume and tumour cellularity) 
is made by a consultant pathologist with significant 
experience in these techniques. 
Extraction of FFPE biopsies
Formalin fixed EUS biopsies underwent DNA extraction 
by the NHS Greater Glasgow & Clyde Molecular Genetics 
Laboratory. Extraction in a clinically approved facility was 
selected as this ensures appropriate quality control for 
clinical trial enrolment and future treatment stratification. 
Sample extraction is performed using 2–4 10 μM tissue curls 
using the Maxwell® 16 FFPE Plus LEV DNA Purification 
Kit (Cat No. AS1135). The Maxwell® 16 System offers 
automation and walk-away purification that saves time 
and labour by eliminating reagent preparation, pipetting 
and centrifugation steps. Briefly, samples are prepared 
by centrifuging tissue curls and adding Proteinase K and 
Incubation buffer (included in Maxwell® Kit Cat No. 
AS1135). This is incubated at 70 ℃ overnight followed by 
the addition of lysis buffer. The sample is now ready for 
DNA purification and is added to the Maxwell® FFPE Plus 
LEV DNA cartridge. Automated extraction and elution are 
performed using elution buffer supplied in the extraction kit. 
Extraction of germline DNA from blood
Germline DNA was obtained by venous blood preserved in 
standard diagnostic EDTA blood tubes. DNA was extracted 
using the DNeasy Blood Mini kit from Qiagen© (Cat No. 
69504). Briefly, 200 μL of whole blood is added to 20 μL of 
Qiagen protease in a 1.5 mL microcentrifuge and incubated 
at 56 ℃ for 10 minutes. Two hundred μL of Ethanol is 
added, and the mixture applied to a DNA spin column. 
This was centrifuged, followed by buffered washing of the 
DNA column. DNA was isolated by elution with buffer 
AE (DNeasy Blood Mini Kit, Qiagen©). DNA yield was 
quantified using the Nanodrop® 2000 spectrophotometer 
and stored at −80 ℃ until sequencing.
Library preparation and sequencing 
Sequencing libraries were created with Lisa Evers 
(Laboratory Scientist) and the Glasgow Precision Oncology 
Laboratory sequencing team.
Whole-genome library preparation
Whole-genome libraries were generated using either 
the Illumina TruSeq DNA LT sample preparation kit 
(Illumina, Part No. FC-121–2001 and FC-121–2001) or the 
Illumina TruSeq DNA PCR-free LT sample preparation 
kit (Illumina, Part No. FC-121–3001 and FC-121–3002) 
according to the manufacturer’s protocols. If available, 1 μg 
of DNA was used as input for fragmentation to ~300 base 
pairs (bp). In the EUS sequencing cohort lower quantities 
of DNA (down to 500 ng) was used for whole genome 
sequencing. Quantification of libraries for clustering was 
performed using the KAPA Library Quantification Kit - 
Illumina/Universal (KAPA Biosystems, Part No. KK4824) 
in combination with the Life Technologies Viia 7 real time 
PCR instrument. 
RNA sequencing library generation and sequencing 
RNA sequencing libraries for patient derived cell lines 
were generated using TruSeq Stranded Total RNA kits 
(catalogue No. RS-122-2203). Due to the relative low 
input of the RNA obtained from EUS biopsy samples, 
RNA sequencing libraries for these were performed 
using the KAPA RNA HyperPrep kit with Riboerase 
(KAPABIOSYSTEMS©, KK8561) designed for small 
input samples on Illumina® systems. Depending on the 
sample size up to 1 μg of RNA was used to produce 
libraries. cDNA was synthesized from the enriched 
and fragmented RNA using Invitrogen’s SuperScript II 
Reverse Transcriptase (catalogue number 18064) and 
random primers. This was converted into double stranded 
DNA and subjected to 15 cycles of PCR to produce RNA-
seq libraries ready for sequencing. Prior to sequencing, 
libraries were examined for quality and quantity using 
an Agilent BioAnalyser and Caliper’s LabChip GX (part 
No. 122000) instruments using the DNA High Sensitivity 
Reagent kit (product No. CLS760672). 
Targeted, whole genome and RNA sequencing 
Sequencing was performed by the Glasgow Precision 
Oncology Laboratory sequencing facility. This is a state-
of-the-art purpose-built facility and has recently obtained 
Good Clinical Laboratory Practice (GCLP) accreditation 
Table S1 Quality control metrics of EUS guided biopsies in paired fresh frozen and FFPE samples
ID DISCORDANT_PCT UNMAPPED_PCT ON_TARGET_MB AVG_DEPTH DUPLICATES_PCT
EUS22FFPE 1.878660931 1.648449209 188.381775 239.1499643 0.414222
EUS23FFPE 1.160586505 1.119745314 481.09095 610.7431758 0.162273
EUS25FFPE 1.090161738 0.851240867 357.447 453.7776401 0.160076
EUS29FFPE 1.307303101 0.987152781 470.521725 597.3255839 0.170565
EUS30FFPE 1.867584474 1.451020795 151.4472 192.2616584 0.293025
EUS32FFPE 1.186870502 1.191414899 408.728625 518.8794728 0.194453
EUS33FFPE 1.294069766 0.956311442 395.7807 502.44213 0.151165
EUS34FFPE 2.900727343 1.885807067 151.306875 192.0835164 0.463899
EUS36FFPE 1.619420087 1.279839973 216.128025 274.3737257 0.25693
EUS37FFPE 2.223729901 2.044954602 192.47835 244.3505511 0.396797
EUS38FFPE 2.160360251 2.874692229 139.130925 176.626193 0.455647
EUS39FFPE 1.553120221 1.360973616 289.620075 367.6716105 0.219366
EUS43FFPE 2.402593409 1.985618201 183.7905 233.3213578 0.458582
EUS44FFPE 1.769249912 1.207252611 272.587275 346.0485341 0.250356
EUS22 1.170933926 0.532084394 145.600425 184.8391993 0.0204255
EUS23 1.037663964 0.507760828 235.5693 299.0543522 0.0237046
EUS23t1 1.163312143 0.505483901 176.148225 223.619518 0.0192176
EUS25 2.055981718 0.198158392 79.054875 100.3598705 0.0242651
EUS29H1 0.935246327 0.075824018 125.460975 159.2722422 0.0280716
EUS30 2.564997083 0.195347506 91.1667 115.7357874 0.0384105
EUS32H1 2.557635438 0.080665822 107.074575 135.9307756 0.0301099
EUS32 1.59910975 0.069204439 89.133975 113.1552505 0.0294499
EUS33 2.283051686 0.56700697 547.1592 694.616574 0.191091
EUS34 1.905538897 0.553729691 638.324025 810.3499811 0.275744
EUS34U1 1.804071111 0.597677584 543.131625 689.5035825 0.232679
EUS36 1.763108158 0.601256045 611.464875 776.2523898 0.172882
EUS37 2.628380109 0.084280942 113.703825 144.3465839 0.0400983
EUS, endoscopic ultrasound; FFPE, formalin fixed paraffin embedded.
to allow clinically valid sample sequencing. Sequencing 
was performed on Illumina platforms according to the 
manufacturer’s instructions. All sequencing runs were 
subjected to quality control according to approved Glasgow 
Precision Oncology Laboratory standard operating 
procedures.
Figure S1 Cryopreservation of EUS biopsy samples. (A) Biopsies are decanted onto a cell strainer to allow separation of blood and fluid from 
biopsy material; (B) biopsies are laid flat on a metal mounting slide to facilitate cryosection at a later stage; (C) metal slide is placed directly on 
dry ice and OCT added to freeze and mount; (D) completed OCT block containing flat mounted EUS biopsies. EUS, endoscopic ultrasound; 
OCT, optimal cutting temperature.
Figure S2 Sequencing strategy of EUS training cohort. Flow chart represents the selection of patient samples undergoing targeted capture, 
whole genome (WGS) and transcriptome (RNAseq) sequencing for both fresh frozen and FFPE samples. EUS, endoscopic ultrasound; 
FFPE, formalin fixed paraffin embedded.
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